RARA and sarcoma: The success stories with targeted therapies directed against PML::RARA and BCR::ABL in acute promyelocytic and chronic lymphocytic leukemia, respectively, but also the more recent clinical experience with inhibitors of kinase fusion proteins found in sarcoma, underscore this notion.